HBW Market News: CHPA Petitions For CBD Reg, PEW Urges Stronger Supplement Oversight
Executive Summary
AHPA releases guidance for tea and infusion products on regulatory and liability implications as a result of increasing Prop 65 lawsuits; CHPA files citizen petition urging FDA to act on a CBD pathway; PEW pushes for stronger supplement oversight; and more.
You may also be interested in...
Cannabinoids Are Test Case For US FDA Advisors’ ‘Predicted Pharmacological Activity’ Discussion
Busy agenda of disparate topics in one-day meeting likely valuable for informing FDA on safety of hemp ingredients but not for moving toward a regulatory pathway for the ingredients' lawful use in supplements and food.
US CBD Supplement Market Anxious For Lawful Use Proposal, And FDA Offers Cannabis Drug Research Guidance
Adding more cannabis-containing drugs to the three already approved in the US relies on research, but hundreds of supplements and other FDA-regulated non-drug products containing CBDs already are available under enforcement discretion by the agency.
‘Time Is Now’ For FDA Rule On Lawful CBD Use In Supplements, CRN Says In Citizen Petition
The trade group’s petition is second on a regulation for CBD’s use in non-drug products submitted to FDA and largely tracks with CHPA’s November 2019 petition. Comments continue to reach the FDA after in March it reopened its docket about establishing a CBD regulation, but with little data the agency says is needed for its decision.